AIIMS Delhi to start trial of intranasal Covid vaccine from Friday

All India Institute Of Medical Science (AIIMS) Delhi is all set to start the booster dose trial of Bharat Biotech’s intranasal COVID-19 vaccine from Friday.

The premier medical institute, All India Institute Of Medical Science (AIIMS) Delhi will commence the booster dose trial of Bharat Biotech’s intranasal COVID-19 vaccine from Friday. 

The institute is one of the five sites where the booster trial for the BBV154 nasal vaccine will be conducted. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine developed by the Hyderabad based company Bharat Biotech. India has not yet approved the use of the intranasal vaccine against COVID-19.

Who will get the trial dose of BBV154 intranasal vaccine?

The intranasal vaccine will be administered to those volunteers who have received both doses of either Covaxin or Covishield vaccines at least five months back but not more than seven months ago, as confirmed by Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS, New Delhi.

“We got the ethical approval for initiating the booster dose trial on Wednesday. Registration for the participants will start from March 10 via email –HYPERLINK “mailto:ctaiims.covid19@gmail.com”ctaiims.covid19@gmail.com — and whatsapp (7428847499) for those who received both the doses of either Covaxin or Covishield more than 5 months but less than 7 months ago,” Dr Rai said, as reported by Financial Express.

The Drugs Controller General of India (DCGI) in January had given permission to Bharat Biotech to conduct a phase-3 randomized, multi-centric study to evaluate the immunogenicity and safety of the booster dose in participants previously vaccinated with Covishield or Covaxin.

Read more:

• AIIMS Delhi launches App with distress button for women employees
• LG Delhi chairs meeting to discuss AIIMS Delhi revamp plans